A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma

Next Previous
Trial Profile

A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs CRS 207 (Primary) ; Tumour cell vaccine-GVAX (Primary) ; Cyclophosphamide
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms ECLIPSE
  • Sponsors Aduro BioTech

    • Most Recent Events

    • 25 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 16 May 2016 Primary endpoint has not been met, (Overall survival in subjects receiving test treatments), according to an Aduro BioTech media release.
    • 08 Mar 2016 According to an Aduro BioTech media release, top-line results from this trial are expected in the second quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top